- Editas has two CRISPR genome editing techniques which are CRISPR/Cas9 and CRISPR/Cas12a.
- EDIT-101 is being developed to treat patients with Leber congenital amaurosis type 10; Results from phase 1/2 BRILLIANCE study expected in 2nd half of 2022.
- EDIT-301 is being developed to treat patients with sickle cell disease and transfusion-dependent beta-thalassemia; this CRISPR makes use of company's proprietary AsCas12a enzyme for genome editing.
- Editas Medicine had $619.9 million in cash as of December 31, 2021, which is enough to fund its operations through at least 2023.
For further details see:
Editas: CRISPR Gene Editing Biotech With Promising Future